Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04232566 · ClinicalTrials.gov registry record
Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
A clinical trial of NASH - Nonalcoholic Steatohepatitis and Obesity, Morbid, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT04232566: Recruiting study of NASH - Nonalcoholic Steatohepatitis and Obesity, Morbid, sponsored by Mayo Clinic.
NCT04232566 is a study of NASH - Nonalcoholic Steatohepatitis and Obesity, Morbid that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 60 participants, below the 260-participant average among 28 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04232566, a study of NASH - Nonalcoholic Steatohepatitis and Obesity, Morbid, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to better understand the relationship between inflammation in adipose tissue (AT), abnormal deposition of fat around the liver and how this affects its appearance and function and ultimately insulin resistance.
Primary Outcome
evaluate the liver fibrosis by elastography before surgical intervention
Conditions Studied
Interventions
- PROCEDURE Bariatric surgery
Study Locations (1)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-02-20 |
| Est. Completion | 2027-12-30 |
What NCT04232566 shows while recruiting
NCT04232566 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 260-participant average among 28 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (77% lower).
The record links to 3 conditions, with NASH - Nonalcoholic Steatohepatitis appearing as the primary indexed condition, and to 1 intervention - of which Bariatric surgery is the first listed.
NCT04232566 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT04232566 about?
NCT04232566 is a clinical study titled "Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity". This study is being done to better understand the relationship between inflammation in adipose tissue (AT), abnormal deposition of fat around the liver and how this affects its appearance and function and ultimately insulin resistance.
What is the current status of trial NCT04232566?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2022-02-20. Estimated completion is 2027-12-30.
What conditions does trial NCT04232566 study?
This clinical trial studies the following conditions: NASH - Nonalcoholic Steatohepatitis, Obesity, Morbid, Chronic Inflammation.
What interventions are being tested in trial NCT04232566?
The interventions under investigation include: Bariatric surgery (PROCEDURE).
Who is sponsoring clinical trial NCT04232566?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04232566 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NASH - Nonalcoholic Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04232566's enrollment target sits among peer trials
60 19th of 28 higher than 9 of 28 other NASH - Nonalcoholic Steatohepatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NASH - Nonalcoholic Steatohepatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
RECRUITING · NA
-
Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis
RECRUITING · NA
-
Estrogen Administration for the Treatment of NASH in Postmenopausal Women
RECRUITING · Phase 3
-
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
RECRUITING · Phase 3
-
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
RECRUITING · Phase 3
-
Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI